Trial Profile
An open-label study of the effect of Tarceva [erlotinib] on treatment response in patients with locally advanced and/or metastatic non-small-cell lung cancer who have not received previous chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2010
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 09 Jan 2008 Status changed from in progress to completed.
- 06 Jun 2006 New trial record.